ストックスクリーナーアプリを入手
1.38
1.43%
-0.02
アフターアワーズ：
1.41
0.03
+2.17%
前日終値:
$1.40
開ける：
$1.38
24時間の取引高:
56,509
Relative Volume:
0.34
時価総額：
$7.93M
収益：
$895.50K
当期純損益:
$-26.30M
株価収益率:
-0.8415
EPS:
-1.64
ネットキャッシュフロー:
$-23.84M
1週間 パフォーマンス:
-3.50%
1か月 パフォーマンス:
-33.97%
6か月 パフォーマンス:
-70.00%
1年 パフォーマンス:
-92.60%
1日の値動き範囲:
$1.36
$1.41
1週間の範囲:
$1.34
$1.48
52週間の値動き範囲:
$1.34
$22.40
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
1.38 | 7.93M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
408.28 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
198.80 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
531.32 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.17 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
157.47 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | Maxim Group | Buy |
| 2024-11-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 開始されました | H.C. Wainwright | Buy |
Mainz Biomed N V (MYNZ) 最新ニュース
Mainz Biomed (NASDAQ:MYNZ) Trading Down 1.9% – Here’s What Happened - Defense World
(MYNZ) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Ca - GuruFocus
Mainz Biomed Initiates Feasibility Study Of PancAlert Blood Test For Pancreatic Cancer Detection - Nasdaq
Mainz Biomed Initiates Feasibility Study Of Biomarker Panel In Pancreatic Cancer Project - MarketScreener
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Cancer Detection | MYNZ Stock News - GuruFocus
Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project - Nasdaq
Mainz initiates feasibility study of biomarker panel in PancAlert project - TipRanks
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - The Manila Times
Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | M - GuruFocus
Mainz Biomed N.V. Secures $4 Million Through Securities Offering - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Trading Up 5.4% – What’s Next? - Defense World
Mainz Biomed (MYNZ) Prices $4M Follow-On Offering - GuruFocus
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - The Manila Times
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | MYNZ Stock News - GuruFocus
Mainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant Amendments - Nasdaq
Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com Nigeria
Trend Tracker for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed to update on CRC screening study by end of summer - Investing.com South Africa
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Mainz Biomed Plans Interim Readout For EAArly DETECT 2 CRC Study - Nasdaq
Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan
MYNZ Stock Update: Maxim Group's Role as Manager | MYNZ Stock News - GuruFocus
Mainz Biomed to hold annual meeting on June 2 - Investing.com Australia
Mainz Biomed to hold annual meeting on June 2 By Investing.com - Investing.com Canada
Mainz Biomed Prepares for June 2025 Annual General Meeting - TipRanks
Stocks of Mainz Biomed N.V (MYNZ) are poised to climb above their peers - Sete News
Investing in Mainz Biomed N.V (MYNZ): What You Must Know - knoxdaily.com
Mainz Biomed Enters into Technology Partnership with EDX Medical Group - MSN
MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus
Strategic Partnership: Mainz Biomed and EDX Medical Join Forces to Transform Early Cancer Detection in UK Market - Stock Titan
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for Co - GuruFocus
Mainz Biomed N.V (NASDAQ: MYNZ) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
Mainz Biomed advances in FDA approval for CRC test By Investing.com - Investing.com South Africa
Mainz Biomed advances in FDA approval for CRC test - Investing.com Australia
The Mainz Biomed N.V (MYNZ) Stock Is Headed for a Correction - uspostnews.com
MYNZ: Mainz Biomed Advances Cancer Detection with New Feasibilit - GuruFocus
Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire
Mainz Biomed's Game-Changing Cancer Test Shows 98% Accuracy as Company Expands European Presence - Stock Titan
Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 48.7% in April - Defense World
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
Mainz Biomed N V (MYNZ) 財務データ
収益
当期純利益
現金流量
EPS
0.43%
0.70%
大文字化:
|
ボリューム (24 時間):